Apex Biotechnology Corp. (TPE:1733)
Taiwan
· Delayed Price · Currency is TWD 28.50
-0.90 (-3.06%)
Mar 9, 2026, 2:36 PM CST
Apex Biotechnology Ratios and Metrics
Market cap in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | Current | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 6, 2026 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
| Market Capitalization | 2,849 | 3,009 | 4,028 | 2,554 | 2,599 | 2,354 | Upgrade
|
| Market Cap Growth | -10.80% | -25.31% | 57.73% | -1.73% | 10.38% | -16.91% | Upgrade
|
| Enterprise Value | 2,400 | 2,667 | 3,842 | 2,337 | 2,292 | 2,222 | Upgrade
|
| Last Close Price | 28.50 | 28.93 | 37.54 | 22.65 | 21.94 | 19.08 | Upgrade
|
| PE Ratio | 19.00 | 23.50 | 34.79 | 14.05 | 12.85 | 24.84 | Upgrade
|
| Forward PE | - | 13.84 | 13.84 | 13.84 | 13.84 | 13.84 | Upgrade
|
| PS Ratio | 1.45 | 1.62 | 2.40 | 1.14 | 1.22 | 1.17 | Upgrade
|
| PB Ratio | 1.57 | 1.65 | 2.24 | 1.41 | 1.48 | 1.43 | Upgrade
|
| P/TBV Ratio | 1.60 | 1.69 | 2.30 | 1.46 | 1.58 | 1.55 | Upgrade
|
| P/FCF Ratio | 13.88 | 10.01 | 19.32 | - | 16.95 | 10.00 | Upgrade
|
| P/OCF Ratio | 12.78 | 9.15 | 17.48 | 95.95 | 14.45 | 8.39 | Upgrade
|
| EV/Sales Ratio | 1.22 | 1.44 | 2.29 | 1.04 | 1.08 | 1.11 | Upgrade
|
| EV/EBITDA Ratio | 11.10 | 14.65 | 18.60 | 8.99 | 7.86 | 11.12 | Upgrade
|
| EV/EBIT Ratio | 15.46 | 20.76 | 27.11 | 13.24 | 11.18 | 21.50 | Upgrade
|
| EV/FCF Ratio | 11.69 | 8.88 | 18.43 | - | 14.95 | 9.44 | Upgrade
|
| Debt / Equity Ratio | 0.06 | 0.07 | 0.09 | 0.10 | 0.16 | 0.31 | Upgrade
|
| Debt / EBITDA Ratio | 0.52 | 0.64 | 0.71 | 0.67 | 0.95 | 2.48 | Upgrade
|
| Debt / FCF Ratio | 0.54 | 0.41 | 0.74 | - | 1.86 | 2.18 | Upgrade
|
| Net Debt / Equity Ratio | -0.25 | -0.26 | -0.16 | -0.12 | -0.19 | -0.19 | Upgrade
|
| Net Debt / EBITDA Ratio | -2.18 | -2.61 | -1.41 | -0.83 | -1.17 | -1.55 | Upgrade
|
| Net Debt / FCF Ratio | -2.19 | -1.58 | -1.39 | 21.76 | -2.22 | -1.31 | Upgrade
|
| Asset Turnover | 0.84 | 0.79 | 0.70 | 0.87 | 0.80 | 0.73 | Upgrade
|
| Inventory Turnover | 2.43 | 1.89 | 1.54 | 2.44 | 2.75 | 3.05 | Upgrade
|
| Quick Ratio | 2.65 | 2.00 | 1.93 | 1.57 | 1.42 | 1.32 | Upgrade
|
| Current Ratio | 4.08 | 3.44 | 3.93 | 2.90 | 2.24 | 1.91 | Upgrade
|
| Return on Equity (ROE) | 8.43% | 7.07% | 6.40% | 10.16% | 11.90% | 5.70% | Upgrade
|
| Return on Assets (ROA) | 4.18% | 3.40% | 3.68% | 4.26% | 4.81% | 2.36% | Upgrade
|
| Return on Invested Capital (ROIC) | 10.26% | 7.53% | 7.49% | 10.65% | 14.91% | 6.26% | Upgrade
|
| Return on Capital Employed (ROCE) | 8.10% | 6.60% | 7.40% | 9.10% | 10.90% | 5.80% | Upgrade
|
| Earnings Yield | 5.31% | 4.25% | 2.87% | 7.12% | 7.78% | 4.03% | Upgrade
|
| FCF Yield | 7.20% | 9.99% | 5.18% | -0.39% | 5.90% | 10.00% | Upgrade
|
| Dividend Yield | 4.08% | 4.15% | 2.93% | 6.18% | 5.93% | 5.76% | Upgrade
|
| Payout Ratio | 79.27% | 85.90% | 120.86% | 71.48% | 54.06% | 115.98% | Upgrade
|
| Buyback Yield / Dilution | -0.17% | -0.08% | 0.34% | 4.70% | 6.53% | -0.05% | Upgrade
|
| Total Shareholder Return | 3.91% | 4.07% | 3.27% | 10.88% | 12.46% | 5.72% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.